Show Summary Details
Page of

Optimizing management in end-stage HF 

Optimizing management in end-stage HF
Optimizing management in end-stage HF

Miriam Johnson

, Karen Hogg

, James Beattie

, and Max Watson

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 27 February 2021

The care of people with heart failure has been transformed over the past 10 -15 years. Guidelines for pharmacological and device management have been developed and service frameworks have improved services and outlook for patients.

In end stage disease, heart failure management is challenging as individuals may not be able to tolerate standard recommended medications. Thus, although the guidelines are helpful, they need to be applied to each patient and reviewed regularly. In addition, as the patient deteriorates, they may find their tablet burden excessive, and rationalising treatment with symptom relief as the focus rather than long term risk reduction is required. This chapter provides a framework within which clinicians can consider the net patient benefit for management in end stage disease.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.